Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Ultrasound Med Biol. 2020 Nov;46(11):2927-2937. doi: 10.1016/j.ultrasmedbio.2020.07.005. Epub 2020 Jul 15.
Lung ultrasound (LUS) has recently been advocated as an accurate tool to diagnose coronavirus disease 2019 (COVID-19) pneumonia. However, reports on its use are based mainly on hypothesis studies, case reports or small retrospective case series, while the prognostic role of LUS in COVID-19 patients has not yet been established. We conducted a prospective study aimed at assessing the ability of LUS to predict mortality and intensive care unit admission of COVID-19 patients evaluated in a tertiary level emergency department. Patients in our sample had a median of 6 lung areas with pathologic findings (inter-quartile range [IQR]: 6, range: 0-14), defined as a score different from 0. The median rate of lung areas involved was 71% (IQR: 64%, range: 0-100), while the median average score was 1.14 (IQR: 0.93, range: 0-3). A higher rate of pathologic lung areas and a higher average score were significantly associated with death, with an estimated difference of 40.5% (95% confidence interval [CI]: 4%-68%, p = 0.01) and of 0.47 (95% CI: 0.06-0.93, p = 0.02), respectively. Similarly, the same parameters were associated with a significantly higher risk of intensive care unit admission with estimated differences of 29% (95% CI: 8%-50%, p = 0.008) and 0.47 (95% CI: 0.05-0.93, p = 0.02), respectively. Our study indicates that LUS is able to detect COVID-19 pneumonia and to predict, during the first evaluation in the emergency department, patients at risk for intensive care unit admission and death.
肺部超声(LUS)最近被提倡作为一种准确的工具来诊断 2019 年冠状病毒病(COVID-19)肺炎。然而,关于其使用的报告主要基于假设研究、病例报告或小型回顾性病例系列,而 LUS 在 COVID-19 患者中的预后作用尚未确定。我们进行了一项前瞻性研究,旨在评估 LUS 在三级急诊评估的 COVID-19 患者中预测死亡率和重症监护病房(ICU)入住的能力。我们样本中的患者中位数有 6 个有病理发现的肺部区域(四分位距 [IQR]:6,范围:0-14),定义为与 0 不同的评分。受累肺部区域的中位数发生率为 71%(IQR:64%,范围:0-100),而中位数平均评分 1.14(IQR:0.93,范围:0-3)。较高的病理肺部区域发生率和较高的平均评分与死亡显著相关,估计差异分别为 40.5%(95%置信区间 [CI]:4%-68%,p=0.01)和 0.47(95%CI:0.06-0.93,p=0.02)。同样,相同的参数与 ICU 入住的风险显著增加相关,估计差异分别为 29%(95%CI:8%-50%,p=0.008)和 0.47(95%CI:0.05-0.93,p=0.02)。我们的研究表明,LUS 能够检测 COVID-19 肺炎,并在急诊科首次评估时预测 ICU 入住和死亡的高危患者。